Adjuvant Zoledronate Duration ‘Could Be Reduced’ For High-Risk Early Breast Cancer
Two years of zoledronate therapy may be adequate for women who undergo surgery for node-positive or high-risk node-negative early breast cancer
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Two years of zoledronate therapy may be adequate for women who undergo surgery for node-positive or high-risk node-negative early breast cancer
A 12-week de-escalated neoadjuvant regimen has achieved high survival rates for HER2-positive, HR-negative early breast cancer patients
Neoadjuvant nivolumab plus chemotherapy could be an option for individuals with early-stage, resectable non-small-cell lung cancer
Using tissue mRNA expression of two genes to choose adjuvant chemotherapy does not significantly improve patient outcomes after complete resection of non-small-cell lung cancer
A two-cycle course of atezolizumab before surgery is feasible for patients with stage I–IIIB non-small-cell lung cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.